Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirati Therapeutics (MRTX)
NASDAQ:MRTX
RESEARCH TOOLSreports
Holding MRTX?
Track your performance easily
See the Price Targets and Ratings of:
MRTX Analyst Ratings
Hold
0 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRTX Stock 12 Month Forecast
Average Price Target
$58.67
▼(-0.05% Downside)
| Highest Price Target$59.00 | Average Price Target$58.67 | Lowest Price Target$58.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Scotiabank
Reiterated
01/24/24
Citi
Downgraded
12/19/23
JMP Securities
Reiterated
11/07/23
Leerink Partners
Downgraded
11/07/23
Stifel Nicolaus
Downgraded
11/06/23
JonesTrading
Assigned
10/20/23
Piper Sandler
Downgraded
10/10/23
TD Cowen
Downgraded
10/10/23
J.P. Morgan
Reiterated
10/09/23
B.Riley Financial
Downgraded
10/09/23
Jefferies
$58
Hold
-1.19%
Downside
Downgraded
10/08/23
Mirati Therapeutics (MRTX) downgraded to Hold from Buy at Jefferies
Oppenheimer
$62
Buy
5.62%
Upside
Reiterated
10/06/23
Oppenheimer Remains a Buy on Mirati Therapeutics (MRTX)
BMO Capital
$72
Hold
22.66%
Upside
Assigned
10/05/23
Hold Rating for Mirati Amid Potential Sanofi Takeout and Lumakras Adcom Decision: A Revised Financial Outlook
Barclays
$71
Buy
20.95%
Upside
Reiterated
08/09/23
Mirati Therapeutics (MRTX) Has a New Rating from Barclays
Morgan Stanley
$37
Hold
-36.97%
Downside
Reiterated
08/09/23
Mirati Therapeutics (MRTX) PT Lowered to $37 at Morgan StanleyMorgan Stanley analyst Michael Ulz lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $37.00 (from $42.00) while maintaining a Equalweight rating.
Best Analysts Covering Mirati Therapeutics
Which Analyst Should I Follow If I Want to Buy MRTX and Sell After:
1 Month
xxx
Success Rate
8/16 ratings generated profit
Average Return
+3.70%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.70% per trade.
3 Months
xxx
Success Rate
10/16 ratings generated profit
Average Return
+15.29%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +15.29% per trade.
1 Year
2 Years
xxx
Success Rate
11/16 ratings generated profit
Average Return
+32.66%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +32.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRTX Analyst Recommendation Trends
Rating
Aug 23
Sep 23
Oct 23
Nov 23
Dec 23
Strong Buy
10
11
7
3
0
Buy
6
10
18
12
8
Hold
8
7
12
11
13
Sell
2
4
3
2
0
Strong Sell
0
0
1
1
1
total
26
32
41
29
22
Each month's total comprises the sum of three months' worth of ratings.
MRTX Financial Forecast
MRTX Stock Forecast FAQ
What is MRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirati Therapeutics’s 12-month average price target is $58.67.
What is MRTX’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MRTX, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRTX a Buy, Sell or Hold?
Mirati Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 5 hold ratings and 0 sell ratings.
What is Mirati Therapeutics’s price target?
The average price target for Mirati Therapeutics is $58.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $59.00 ,the lowest forecast is $58.00. The average price target represents -0.05% Decrease from the current price of $58.7.
The highest analyst price target is $59.00 ,the lowest forecast is $58.00. The average price target represents -0.05% Decrease from the current price of $58.7.
What do analysts say about Mirati Therapeutics?
Mirati Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of MRTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.